Life Extension Update
Reduced vitamin D levels associated with infection in ICU patients
Friday, July 19, 2013. A study conducted by Korean researchers, published in the June 2013 issue of Neural Regeneration Research, revealed a greater risk of deficient serum levels of vitamin D in patients who had undergone treatment at a neurosurgical intensive care unit (ICU).
Je Hoon Jeong, MD, PhD, of Soon Chun Hyang University Bucheon Hospital and colleagues evaluated serum 25-hydroxyvitamin D and 1,25-dihydroxyvitamin D in 55 men and women who were hospitalized at a neurosurgical ICU. The results of blood testing for white blood cell count and neutrophil percentage indicated suspected infection in 15 patients, which was confirmed by sputum, urine or blood bacterial culture in ten patients.
Two weeks after ICU admission, average serum 25-hydroxyvitamin D levels decreased to deficient levels defined as less than 10 nanograms per milliliter (ng/mL) and serum 1,25-dihydroxyvitamin D levels became deficient after four weeks. The researchers observed a trend toward increased white blood cell counts and neutrophil percentages in association with declining levels of vitamin D. In comparison with subjects who did not have signs of infection, serum 25-hydroxyvitamin D levels were significantly lower in both those with suspected and confirmed infection at all time points up to 28 days following admission.
The authors note that research has demonstrated a role for vitamin D in regulating normal innate and adaptive immunity, and that the active form of the vitamin has been shown to stimulate the innate immune system by elevating the production of interleukin-1 and increasing the proliferation of monocytes (a type of white blood cell). "Vitamin D supplementation has been demonstrated to yield good effects for infectious diseases including pneumonia," they write. "The optimal dosage of vitamin D required to both normalize the deficiency observed in the intensive care unit setting and potentially have a favorable effect on infection and other outcomes is currently unknown and requires further study."
"Future studies should clarify whether vitamin D supplementation can improve survival in patients admitted to the neurosurgical intensive care unit," they conclude.
Ceraphyl® is a registered trademark of International Specialty Products. QuSome® is a registered trademark of BioZone Laboratories, Inc.
This supplement should be taken in conjunction with a healthy diet and regular exercise program. Individual results are not guaranteed and results may vary.
The information provided on this site is for informational purposes only and is not intended as a substitute for advice from your physician or other health care professional or any information contained on or in any product label or packaging. You should not use the information on this site for diagnosis or treatment of any health problem or for prescription of any medication or other treatment. You should consult with a healthcare professional before starting any diet, exercise or supplementation program, before taking any medication, or if you have or suspect you might have a health problem. You should not stop taking any medication without first consulting your physician.
If you are not 100% satisfied with any purchase made directly from Life Extension®, just return your purchase within 12 months of original purchase date and we will either replace the product for you, credit your original payment method or credit your Life Extension account for the full amount of the original purchase price (less shipping and handling).
These statements have not been evaluated by the Food and Drug Administration.
These products are not intended to diagnose, treat, cure, or prevent any disease.